
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Click the title above for a link to open the Pharmaceutical Executive July/August 2024 issue in an interactive PDF format.
over 2 years ago
An AI Pulse Checkover 2 years ago
Divergent Paths: Pharm Exec Profiles Five Recent Drug Launchesover 2 years ago
A Promising Option: Exxuaover 2 years ago
Opening the Door: Omvohover 2 years ago
'Marked’ for Stardom?: Truqapover 2 years ago
Branching Off: Wegovyover 2 years ago
A Formidable First: Winrevairover 2 years ago
The Future of Launch Excellence is Generative AIover 2 years ago
From Potential to Value: Carving a Slice of the CGT ‘PIE'over 2 years ago
Big Bets, Bold Steps





